Ocera Therapeutics Inc (OCRX)

2.81
NASDAQ : Health Care
Prev Close 2.81
Day Low/High 2.80 / 2.83
52 Wk Low/High 1.76 / 4.57
Avg Volume 48.40K
Exchange NASDAQ
Shares Outstanding 21.31M
Market Cap 59.87M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ocera To Present At The 2016 BIO International Convention

Ocera To Present At The 2016 BIO International Convention

-- Company Presentation Scheduled for June 8, 2016 at 1:00 PM PT --

Ocera Therapeutics Announces Publication Of Promising Preclinical Data In Support Of Its Ammonia Scavenger OCR-002 In The Journal Of Hepatology

Ocera Therapeutics Announces Publication Of Promising Preclinical Data In Support Of Its Ammonia Scavenger OCR-002 In The Journal Of Hepatology

Data show OCR-002 significantly reduced plasma ammonia and portal pressure in portal hypertensive rat models

Ocera To Present At The 15th Annual Needham Healthcare Conference

Ocera To Present At The 15th Annual Needham Healthcare Conference

Company Presentation Scheduled for April 13, 2016 at 3:40 PM ET

Ocera To Present At The Cowen And Company 36th Annual Health Care Conference

Ocera To Present At The Cowen And Company 36th Annual Health Care Conference

Company Presentation Scheduled for March 7, 2016 at 3:20 PM ET

Ocera To Present At The 18th Annual BIO CEO & Investor Conference

Ocera To Present At The 18th Annual BIO CEO & Investor Conference

Company Presentation Scheduled for February 9, 2016 at 10:00 AM ET

Ocera Announces Complete Plasma Data From Pilot Phase 1 Study For Orally-Available OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy

Ocera Announces Complete Plasma Data From Pilot Phase 1 Study For Orally-Available OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy

Study Demonstrated a Robust, Extended-Release Profile for All OCR-002 Prototype Extended-Release Formulations Evaluated

Ocera (OCRX) Stock Rises on Positive Drug Trial Results

Ocera (OCRX) Stock Rises on Positive Drug Trial Results

Ocera (OCRX) stock is gaining in late afternoon trading on Tuesday, after the bio-pharmaceutical company reported positive drug trial results.

Ocera Announces Positive Phase 1 Results For Oral OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy

Ocera Announces Positive Phase 1 Results For Oral OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy

Preliminary Pharmacokinetic Data Demonstrate Promising Extended-Release Profiles

Ocera Therapeutics Highlights OCR-002 Data To Be Presented At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

Ocera Therapeutics Highlights OCR-002 Data To Be Presented At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

6 Accepted Abstracts Underscore the Potential Breadth of Therapeutic Application for OCR-002

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for under $10 a share look ready to break out and trade higher from current levels.

Ocera Initiates Phase 1 Clinical Trial Of Oral Drug Candidate OCR-002 For Prevention Of Hepatic Encephalopathy

Ocera Initiates Phase 1 Clinical Trial Of Oral Drug Candidate OCR-002 For Prevention Of Hepatic Encephalopathy

Company Strengthens Leadership Team With Two New Hires

Ocera Therapeutics Secures $20 Million Debt Facility From Oxford Finance And Silicon Valley Bank

Ocera Therapeutics Secures $20 Million Debt Facility From Oxford Finance And Silicon Valley Bank

Funding Extends Cash Resources to Mid-2017

Insider Trading Alert - SWHC, MTSI And OCRX Traded By Insiders

Insider Trading Alert - SWHC, MTSI And OCRX Traded By Insiders

Stocks with insider trader activity include SWHC, MTSI and OCRX

Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders

Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders

Stocks with insider trader activity include DXCM, FDP and OCRX